First Joint Clinical Assessment (JCA) Report Published: Implications for Evidence Strategy in Europe

Initial analysis highlights that JCA sets a high bar for evidence strategy. Expectations around comparator selection, outcome definition, and statistical methodology are rigorous, with limited tolerance for gaps or assumptions. The report demonstrates a willingness by assessors to critically evaluate evidence generation strategies, challenge the suitability of submitted comparator data, and exclude evidence where study methods and results could not be adequately assessed. Submissions must be comprehensive and defensible, with clear rationale for methodological choices and full transparency in data reporting. In several areas, including indirect treatment comparisons and time-to-event analyses, assessors demonstrate a willingness to challenge approaches and undertake their own analyses where evidence is incomplete. These observations suggest that future submissions will require not only robust clinical data, but also a clear and defensible strategy for comparator selection and comparative evidence generation from an early stage.

For health technology developers preparing for future submissions, the implications are clear: success under JCA will depend on early planning, robust evidence generation, and proactive narrative development. This is not simply a regulatory requirement, but a strategic exercise in anticipating scrutiny, aligning evidence to stakeholder expectations, and ensuring that the value story is fully supported. As the framework continues to evolve, staying ahead of these requirements will be critical to achieving favourable outcomes in the European market.

Acumetis Global Value & Access is actively supporting clients through JCA readiness and submission strategy, including work on three current JCA submissions. To discuss how these requirements may affect your evidence strategy, reach out to our Global Value & Access team.